The Value of CERAMENT® G

Removing Financial Barriers for Patients and Providers 

CERAMENT®G with Gentamicin has been designated by the FDA as a “Breakthrough Device”. This designation has allowed easier access to reimbursement programs through the Centers for Medicare and Medicaid Services (CMS) for both the inpatient and outpatient settings.  The purpose of these programs is to expand patient access to new technology that CMS deems as worth adopting and help ease the decisions between cost and care.

Inpatient Reimbursement Program

In August of 2025 CMS approved CERAMENT G for a New Technology Add-On Payment for the indication open fractures. New Technology Add-On Payment (NTAP) is intended to provide inpatient admissions with additional payment for the use of CERAMENT G with Gentamicin when the hospital costs exceed the payment threshold. Payment varies based on costs exceeding the payment threshold with a max payment of $5,687.50.

The case must be coded with the ICD-10-PCS procedure XW0V0P7 (i.e., CERAMENT G was used in the surgery), but without any of the ICD-10-CM diagnosis codes in the category M86 (Osteomyelitis). Those cases with an M86 code do not qualify for this NTAP.

Note: During October 2023 to September 2025, CERAMENT G had an active NTAP for the indication bone infection. The NTAP for the first indication was discontinued after three years’ duration.